Log In
BCIQ
Print this Print this
 

GNF6702

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionSelective inhibitor of the kinetoplastid proteasome
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Infectious (unspecified)
Indication DetailsTreat Leishmania donovani, Trypanosoma cruzi and T. brucei infections
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today